Followers | 177 |
Posts | 24397 |
Boards Moderated | 12 |
Alias Born | 04/03/2002 |
Tuesday, May 30, 2023 10:19:44 AM
May 30, 2023 (BusinessWire)
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform intended for patient use at home, today announced that it has entered into a Strategic Alliance Agreement (SAA) with Samsung, extending the existing SAA between LIVMOR and Samsung. HeartBeam acquired the assets of LIVMOR earlier this year.
Under the terms of the agreement, HeartBeam and Samsung will identify and define opportunities for collaboration, tapping the HeartBeam team's expertise and patented technology in the assessment and monitoring of cardiac symptoms.
"The goal of this partnership is to bring standard of care for cardiac diagnostic capabilities to patients by utilizing cutting edge technologies of both Samsung and HeartBeam," said Branislav Vajdic, Ph.D., HeartBeam CEO and Founder. "Our newly acquired state of the art, FDA cleared, Samsung watch-based arrhythmia detection tool, once integrated with the HeartBeam AIMIGo(TM) telehealth platform, presents a unique opportunity to extend our product capabilities well beyond what is currently available for cardiac patients outside of a medical setting."
Kevin Jones, Senior Director, Federal Healthcare, Samsung Electronics America, added, "The strategic collaboration between Samsung and LIVMOR was very successful, resulting in an FDA cleared solution for Atrial Fibrillation detection centered around the Samsung Galaxy watch and tablet running Samsung's defense-grade cyber-security system, Knox. We are excited that LIVMOR is now part of HeartBeam and look forward to continuing our successful collaboration. The potential of combining LIVMOR's technology and the HeartBeam AIMIGo system holds significant promise to address major cardiac conditions for our veterans."
Founded in 2016, LIVMOR developed the Halo(TM) Atrial Fibrillation (AF) Detection System, the world's first FDA-cleared prescription wearable for continuous cardiac rhythm monitoring. The Halo system provides continuous monitoring of pulse rhythms for the detection of AF on-demand during the day and automatically overnight. Under the previous SAA, LIVMOR and Samsung developed a physician-prescribed and fully integrated patient care platform that provides extended monitoring of patient cardiovascular health in virtually any setting, using medical grade equipment. LIVMOR's technology was commercially deployed within the VA Healthcare System in Dallas, Texas.
"Thanks to our cooperation with LIVMOR and Samsung, we are able to treat some of the nation's most at-risk patients as safely and effectively from the comfort of their homes as we would if they were sitting in an exam room," said Dr. Jerrold Grodin, Department of Veterans Affairs, North Texas. "We've seen an increase in early adoption from patients when their physicians are also early adopters."
Among the available opportunities is a potential collaboration with the Department of Veterans Affairs through its Accelerating VA Innovation and Learning (AVAIL) program. In September, the VA announced that 17 companies had won spots in a potential five-year, $650 million healthcare technology research and development program. Participants provide subject-matter expertise to help the agency design, build and test novel platforms, services and care models that could be scaled into clinical production to support the Veterans Health Administration.
One of the AVAIL program's awardees is Longview International Technology Solutions (LTS), a systems integration company. LIVMOR and Samsung have been designated as official collaborators with LTS for the AVAIL project. With the Company's anticipated participation in the AVAIL project, HeartBeam could share its expertise in the assessment and monitoring of cardiac symptoms as it collaborates with Samsung to innovate and develop solutions for the VA, the largest integrated healthcare system in the U.S.
"Veterans reported a rate of heart attacks more than twice that of non-veterans in one study," Dr. Vajdic added. "This shows that coronary artery disease is a significant problem for veterans, making improvements in heart attack detection at the VA particularly critical."
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to assess their cardiac symptoms quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo(TM) is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms. HeartBeam AIMI and HeartBeam AIMIGo have not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies. For more information, visit http://www.HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our in our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230530005171/en/
SOURCE: HeartBeam, Inc.
Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us
Media Contact:
media@heartbeam.com
Recent BEAT News
- HeartBeam to Host First Quarter 2023 Results Conference Call on Thursday May 9, 2024 at 4:30 p.m. Eastern Time • Business Wire • 04/25/2024 12:31:00 PM
- HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias • Business Wire • 04/09/2024 12:31:00 PM
- HeartBeam Reports Fourth Quarter and Full Year 2023 Financial Results • Business Wire • 03/20/2024 08:05:00 PM
- First Patients Enrolled in Pivotal Study Evaluating HeartBeam’s AIMIGo™ System for Synthesizing a 12-Lead ECG • Business Wire • 03/14/2024 12:31:00 PM
- HeartBeam Receives Two New US Patents for its Core Cardiac Monitoring Technology • Business Wire • 03/07/2024 01:31:00 PM
- HeartBeam to Host Fourth Quarter and Full Year 2023 Results Conference Call on Wednesday March 20, 2024 at 4:30 p.m. Eastern Time • Business Wire • 03/05/2024 01:31:00 PM
- HeartBeam Unveils AI Program Designed to Deliver Unprecedented Personalized Cardiac Insights • Business Wire • 12/14/2023 01:31:00 PM
- HeartBeam Reports Third Quarter 2023 Financial Results • Business Wire • 11/14/2023 09:01:00 PM
- HeartBeam Announces Expansion of Its Scientific Advisory Board • Business Wire • 11/09/2023 01:31:00 PM
- HeartBeam Granted Third US Patent for 12-Lead Extended Wear Patch for Detecting Heart Attacks and Complex Cardiac Arrythmias • Business Wire • 11/07/2023 01:31:00 PM
- HeartBeam to Host Third Quarter 2023 Results Conference Call on Tuesday November 14, 2023 at 4:30 p.m. Eastern Time • Business Wire • 10/31/2023 12:31:00 PM
- Implicity Expands Senior Leadership Team with New U.S. Chief Commercial Officer • PR Newswire (US) • 09/27/2023 12:05:00 PM
- HeartBeam Appoints Richa Gujarati and Pooja Chatterjee to Senior Management Team • Business Wire • 09/26/2023 12:31:00 PM
- Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference • GlobeNewswire Inc. • 09/21/2023 01:35:00 PM
- HeartBeam Reports Second Quarter 2023 Financial Results • Business Wire • 08/10/2023 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:00:36 PM
- HeartBeam Announces Publication of Foundational Study on the Detection of Heart Attacks • Business Wire • 08/09/2023 12:31:00 PM
- HeartBeam Appoints Deborah Castillo as Vice President of Regulatory Affairs • Business Wire • 08/08/2023 12:31:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2023 01:43:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2023 01:41:10 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2023 10:39:25 PM
- HeartBeam to Host Second Quarter 2023 Results Conference Call on Thursday August 10, 2023 at 4:30 p.m. Eastern Time • Business Wire • 07/27/2023 12:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/26/2023 12:35:33 PM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM